Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 15/20 | 0.65 |
| ▸ | CTSG | P08311 | 1/20 | 0.47 |
| ▸ | MALT1 | Q9UDY8 | 2/20 | 0.38 |
| ▸ | MLYCD | O95822 | 1/20 | 0.37 |
| ▸ | ACACB | O00763 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6740115 | 0.88 | ELANE (0.70) | ELANECTSGMALT1MLYCDEPHX2 | |
| SCHEMBL6741140 | 0.87 | ELANE (0.61) | ELANECTSG | |
| SCHEMBL7335282 | 0.84 | ELANE (0.91) | ELANECTSGMALT1 | |
| SCHEMBL29941605 | 0.84 | ELANE (0.91) | ELANECTSGMALT1 | |
| SCHEMBL7863699 | 0.81 | ELANE (0.62) | ELANECTSGMALT1MLYCDACACB | |
| SCHEMBL7859514 | 0.81 | ELANE (0.62) | ELANECTSGMALT1MLYCDACACB | |
| SCHEMBL7963859 | 0.81 | ELANE (0.85) | ELANECTSGMALT1 | |
| SCHEMBL7333552 | 0.79 | ELANE (1.00) | ELANECTSGMALT1 | |
| SCHEMBL7330574 | 0.79 | ELANE (0.95) | ELANECTSGMALT1 | |
| SCHEMBL7861402 | 0.77 | ELANE (0.85) | ELANECTSGMALT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030096759-A1 | Novel elastase inhibitors | AVENTISUB II INC. | 2003-05-22 | — | — | US | claimed |
| EP-0804465-A1 | NOVEL ELASTASE INHIBITORS | HOECHST MARION ROUSSEL, INC. (US) | 1997-11-05 | — | — | EP | claimed |
| WO-1995033763-A1 | NOVEL ELASTASE INHIBITORS | HOECHST MARION ROUSSEL, INC. (US) | 1995-12-14 | — | — | WO | claimed |
| US-6693072-B2 | Elastase inhibitors | AVENTIS PHARMACEUTICALS INC. | 2004-02-17 | — | — | US | disclosed |
| EP-0804465-B1 | NOVEL ELASTASE INHIBITORS | AVENTIS PHARMA INC (US) | 2003-08-06 | — | — | EP | disclosed |
| US-20030096759-A1 | Novel elastase inhibitors | AVENTISUB II INC. | 2003-05-22 | — | — | US | disclosed |
| EP-0804465-A1 | NOVEL ELASTASE INHIBITORS | HOECHST MARION ROUSSEL, INC. (US) | 1997-11-05 | — | — | EP | disclosed |
| WO-1995033763-A1 | NOVEL ELASTASE INHIBITORS | HOECHST MARION ROUSSEL, INC. (US) | 1995-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096759-A1 | Novel elastase inhibitors | ELANE, SERPINB1, MMP8 | ELANE 1/4885CTSG 91/4885MALT1 3533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.